TOI — Oncology Institute Income Statement
0.000.00%
- $39.01m
- $61.56m
- $324.24m
- 27
- 73
- 18
- 33
Annual income statement for Oncology Institute, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 155 | 188 | 203 | 252 | 324 |
Cost of Revenue | |||||
Gross Profit | 29.9 | 36.9 | 40.8 | 52.1 | 59.6 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 158 | 196 | 244 | 334 | 401 |
Operating Profit | -2.64 | -8.2 | -40.9 | -81.8 | -77 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.64 | -14.8 | -11.6 | -0.091 | -83.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.02 | -14.3 | -10.9 | 0.152 | -83.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.02 | -14.3 | -10.9 | 0.152 | -83.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.02 | -14.3 | -10.9 | 0.068 | -67.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.054 | -0.192 | -0.193 | 0.163 | -0.729 |
Dividends per Share |